+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies



Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies



Pharmacology and Therapeutics 165: 50-62



Pulmonary arterial hypertension (PAH) is a syndrome characterised by an increase in pulmonary vascular resistance. This results in elevated resting pulmonary artery pressure and leads to progressive right ventricular (RV) failure, secondary to increased afterload. Although initially thought to be a disease driven primarily by endothelial dysfunction with a resultant vasoconstrictor versus vasodilator imbalance, it has become increasingly apparent that the rise in pulmonary vascular resistance that causes RV failure is also attributable to pulmonary vascular remodelling. This inflammatory, hyper-proliferative and anti-apoptotic phenotype is accompanied by a metabolic switch from physiological mitochondrial oxidative phosphorylation to aerobic glycolysis. The molecular pathways triggering this cellular metabolic shift have been the subject of extensive investigation, as their discovery will inevitably lead to new therapeutic targets. Reactive oxygen/nitrogen species (ROS/RNS) including hydrogen peroxide, superoxide and peroxynitrite are second messenger molecules that are involved in functional oxidative and nitrosative modification of proteins. Dysregulation of oxidative signalling caused by an excess of ROS and RNS relative to antioxidants has been heavily implicated in the underlying pathophysiology of PAH and likely participates in this metabolic reprogramming. This review will focus on the role of oxidative signalling and redox reactions to the molecular pathology of PAH. In addition, promising novel therapeutic agents targeting these pathways will be discussed.

(PDF emailed within 0-6 h: $19.90)

Accession: 058488677

Download citation: RISBibTeXText

PMID: 27216365

DOI: 10.1016/j.pharmthera.2016.05.005


Related references

Cellular interplay in pulmonary arterial hypertension: implications for new therapies. Biochimica et Biophysica Acta 1843(5): 885-893, 2014

Dose proportionality and pharmacokinetics of dronedarone following intravenous and oral administration to rat. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 2018: 1-6, 2018

Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 142(5): 1150-1157, 2013

Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radical Biology and Medicine 56: 28-43, 2014

Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Current Opinion in Cardiology 23(6): 545-554, 2008

Systemic sclerosis related pulmonary hypertension associated with interstitial lung disease Impact of pulmonary arterial hypertension therapies. 2011

Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation 128(5): 475-476, 2013

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 129(1): 57-65, 2014

Oxidative and nitrosative stress in pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide. Vascular Pharmacology 45(5): 308-316, 2006

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. Journal of Heart and Lung Transplantation 34(3): 356-361, 2015

Comparison of Oryza sativa and Oryza brachyantha Genomes Reveals Selection-Driven Gene Escape from the Centromeric Regions. Plant Cell 30(8): 1729-1744, 2018

Letter by Bertoletti et al regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". Circulation 130(12): E108-E108, 2014

Letter by Suissa and GaliƩ regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". Circulation 130(12): E107-E107, 2014

Letter by Ogawa and Matsubara regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". Circulation 130(12): E109-E109, 2014